Carcinoid Tumor |
NCT02147951: Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma |
|
|
| No Longer Available | 3b | | US | Talimogene Laherparepvec | Amgen | Unresected Stage IIIb to IVM1c Melanoma | | | | |
OCCLURANDOM, NCT02230176: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II |
|
|
| Recruiting | 2 | 80 | Europe | Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Advanced Accelerator Applications | Pancreatic Neuroendocrine Carcinoma | 10/23 | 10/23 | | |
| No Longer Available | N/A | | US | CP-675,206 | Pfizer | Advanced Unresectable Melanoma | | | | |
NCT00495066: Compassionate Use Trial for Unresectable Melanoma With Ipilimumab |
|
|
| No Longer Available | N/A | | RoW | Ipilimumab | Bristol-Myers Squibb | Melanoma | | | | |
|
|
|
|
|
|
|
|
|
NCT01728051: Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver |
|
|
| No Longer Available | N/A | | US | Melphalan, Percutaneous Hepatic Perfusion | Delcath Systems Inc. | Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma | | | | |
CheckMate 218, NCT02186249: Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma |
|
|
| No Longer Available | N/A | | US, Canada | Nivolumab, Ipilimumab | Bristol-Myers Squibb | Malignant Melanoma | | | | |
|
NCT02416232 / 2014-005149-40: Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma |
|
|
| No Longer Available | N/A | | Europe | Trametinib, Dabrafenib | GlaxoSmithKline | Melanoma | | | | |
NCT02083484: Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) |
|
|
| No Longer Available | N/A | | NA | Pembrolizumab | Merck Sharp & Dohme LLC | Melanoma | | | | |
|
|
|
| No Longer Available | N/A | | US, Canada, RoW | Nivolumab | Bristol-Myers Squibb | Stage III (Unresectable) or Stage IV Advanced Melanoma | 05/18 | 05/18 | | |